EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

Yoon-Koo Kang iD, Shukui Qin, Keun-Wook Lee, Sang Cheul Oh, In-Ho Kim, Jong Gwang Kim, Yong Li, Zhuchen Yan, Jin Li, Li-Yuan Bai, Catherine Chan, Akeem Yusuf und 3 weitere

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01516-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Gastric Cancer, 2024. Verfasst von Yoon-Koo Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Asan Medical Centre, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea. ykk…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Fluorouracil. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the FIGHT study (NCT03694522) bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 showed clinically meaningful efficacy in patients with FGFR2b-positive (2+/3+ membranous staining by immunohistochemistry) locally advanced unresectable/metastatic gastric/gastroesophageal cancer (G/GEJC). A meaningful proportion of patients in FIGHT were enrolled in East Asia, reflecting global epidemiology of G/GEJC.

Methods

This subgroup analysis of the global, phase 2, double-blind FIGHT study included all patients enrolled in East Asian sites. Patients were randomized 1:1 to bemarituzumab-mFOLFOX6 (15 mg/kg and one 7.5 mg/kg dose on cycle 1, day 8) or matching placebo-mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months.

Results

The East Asian subgroup comprised 89 patients (57% of overall study population); 45 were randomized to bemarituzumab-mFOLFOX6 and 44 to placebo-mFOLFOX6. Median PFS (95% confidence interval [CI]) was 12.9 months (8.8–17.9) with bemarituzumab-mFOLFOX6 and 8.2 months (5.6–10.3) with placebo-mFOLFOX6 (HR 0.50, 95% CI 0.29–0.87); median OS (95% CI) was 24.7 months (13.8–33.1) vs 12.9 months (9.3–21.4), respectively (HR 0.56, 95% CI 0.32–0.96). Treatment benefit was more pronounced in patients with FGFR2b-positive G/GEJC in ≥ 10% of tumor cells. No new safety signals were reported.

Conclusion

In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEsophagogastric JunctionFluorouracilLeucovorinOrganoplatinum CompoundsReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodEast Asian PeopleEsophageal NeoplasmsSurvival Rate

Stichwörter der Autor:innen

BemarituzumabFGFR2bGastric cancerTargeted therapymFOLFOX6

Substanzen

Antibodies, Monoclonal, HumanizedFGFR2 protein, humanFluorouracilLeucovorinOrganoplatinum CompoundsReceptor, Fibroblast Growth Factor, Type 2

Autor:innen und Institutionen

  • Department of Oncology Asan Medical Centre, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea. ykkang@amc.seoul.kr.
  • Nanjing Tianyinshan Hospital, The First Affiliated Hospital of China Pharmaceutical University, Nanjing, China.
  • Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-Do, South Korea.
  • Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.
  • Department of Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Kyungpook National University Chilgok Hospital, Daegu, South Korea.

ORCID-Profile: Yoon-Koo Kang

Förderung

  • Amgen

Zitieren

APA

Kang, Y. K., Qin, S., Lee, K. W., Oh, S. C., Kim, I. H., Kim, J. G., Li, Y., Yan, Z., Li, J., Bai, L. Y., Chan, C., Yusuf, A., Zahlten-Kümeli, A., Taylor, K., & Yamaguchi, K. (2024). Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer. https://doi.org/10.1007/s10120-024-01516-3

Vancouver

Kang YK, Qin S, Lee KW, Oh SC, Kim IH, Kim JG, et al. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer. 2024. doi:10.1007/s10120-024-01516-3

BibTeX
@article{Kang2024,
  author = {Kang, Yoon-Koo and Qin, Shukui and Lee, Keun-Wook and Oh, Sang Cheul and Kim, In-Ho and Kim, Jong Gwang and Li, Yong and Yan, Zhuchen and Li, Jin and Bai, Li-Yuan and Chan, Catherine and Yusuf, Akeem and Zahlten-Kümeli, Anita and Taylor, Kate and Yamaguchi, Kensei},
  title = {Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01516-3}
}
Kostenlos starten →